ELCOME MEAE - mf.vu.lt€¦ · 18 FINAL PROGRAMME...

3w w w . e a d o 2 0 2 0 . c o m

WELCOME MESSAGE16th EADO CONGRESS

Dear Colleagues,

Due to the Coronavirus crisis the scientific committee, congress presidents and the congress organization decided to organize the 16th EADO Congress as an interactive virtual meeting on October 12th – 14th 2020 CENTRAL EUROPEAN TIME (CET).

Although Lithuania is managing COVID-19 situation quite well, there is a level on uncertainty in Europe with the travel situation. Even thereafter it is unclear that meetings like this can happen in Europe.

The virtual EADO Congress will host an own congress platform with interactive features, a plenary hall, a virtual industrial exhibition, poster exhibition, etc. The sessions will take place live, with virtual presence of the chairperson and the speakers, questions will be possible through a Q&A sessions. The EADO Executive board members will be available onsite to support symposiums and facilitate effective discussions.

As a registered participant you will have access to the on-demand service. You will have the opportunity to discuss live with the chairs and faculty members, or you can follow the sessions and view the presentations afterwards until the end of the year.

With your support we will make this meeting at the highest scientific level.

We look forward to welcoming you ONLINE in October 2020

Prof. Dr. Claus GarbeProf. Dr. Matilda Bylaitė-Bučinskienė

PROGRAMME AT A GLANCE16th EADO CONGRESS

4 F I N A L P R O G R A M M E

Monday, October 12ALFA HALL BETA HALL ZETA HALL

09:00 – 09:15 OPENING CEREMONY

09:15 - 12:30 DERMATOSCOPY COURSE 1 SKIN CARE IN ORGAN TRANSPLANT PATIENTS EUROPE SATELLITE SYMPOSIUM AT THE EADO

12:30 - 13:15 BREAK, VIRTUAL EXHIBITION & E-POSTER VIEWING

13:15 – 14:15 KEYNOTE LECTURES 1Skin cancer preventionClassification of melanoma

14:30 – 15:30 INDUSTRY SATELLITE SYMPOSIUM 1

15:30 – 17:00 SYMPOSIUM 1Advanced BCC classification and treatment

SYMPOSIUM 2Challenging cases: dermoscopy quiz

SYMPOSIUM 3Biology of skin cancer

17:00 – 17:30 BREAK, VIRTUAL EXHIBITION & E-POSTER VIEWING

17:30 – 18:45 SYMPOSIUM 4Management of nevi

SYMPOSIUM 5Barriers to access to innovative medicines and successful access schemes in Europe: multistakeholder panel discussion

SYMPOSIUM 6Occupational skin cancers

Tuesday, October 13ALFA HALL BETA HALL ZETA HALL

08:30 – 10:00 SYMPOSIUM 7New diagnostic devises in skin cancers

SYMPOSIUM 8Predictive markers for immunotherapy in melanoma


10:30 – 12:00 SYMPOSIUM 9Medical treatment of melanoma

SYMPOSIUM 10Melanoma surgery

FREE COMMUNICATIONS 1


13:15 – 14:15 KEYNOTE LECTURES 2Cancer syndromesHow does immunotherapy work in cancer


SYMPOSIUM 11Update on management of actinic keratoses

WORKSHOP 1Spitzoid tumors


16:00 – 17:00 NDUSTRY SATELLITE SYMPOSIUM 4

SYMPOSIUM 12Skin cancer prevention & screening

17:00 – 18:30 SYMPOSIUM 13Adjuvant treatment in melanoma

SYMPOSIUM 14The new European BCC guidelines


5w w w . e a d o 2 0 2 0 . c o m

Dermatoscopy course

Skin care in organ transplant patients Europe satellite symposium at the eado skin care in organ transplant patients europe satellite symposium at the EADO

Keynote lecturesOpening ceremony Industry satellite symposium

Closing ceremony & awards

Symposium

Wednesday, October 14ALFA HALL BETA HALL ZETA HALL

08:30 – 10:00 SYMPOSIUM 15Advanced SCC

SYMPOSIUM 16Who should receive adjuvant therapy in melanoma


10:30 – 12:00 SYMPOSIUM 17Difficult to treat subtypes of melanoma

SYMPOSIUM 18The new European SCC guidelines



13:15 – 14:15 KEYNOTE LECTURES 3What is new in melanoma?What is new in keratinocyte skin cancer?


SYMPOSIUM 19Local therapies in melanoma

WORKSHOP 2Photodynamic therapy


16:00 – 16:58 SYMPOSIUM 20Metastatic Melanoma: Challenges

SYMPOSIUM 21Management of cutaneous toxicities

17:00 – 18:30 SYMPOSIUM 22Cutaneous lymphoma

SYMPOSIUM 23Rare skin tumors


18:30 – 19:00 CLOSING CEREMONY & AWARDS

SCIENTIFIC POGRAMME16th EADO CONGRESS


12-14 OCTOBER, 2020, VIRTUAL CONGRESS, CENTRAL EUROPEAN TIME

Monday, October 12

Mon

day,

Oct

ober

12 ALFA HALL BETA HALL ZETA HALL

09:00 – 09:15 OPENING CEREMONY

09:15 – 12:30 DERMATOSCOPY COURSE 1 SKIN CARE IN ORGAN TRANSPLANT PATIENTS EUROPE SATELLITE SYMPOSIUM AT THE EADO


13:15 – 14:15 KEYNOTE LECTURES 1Skin cancer preventionClassification of melanoma


15:30 – 17:00 SYMPOSIUM 1Advanced BCC classification and treatment

SYMPOSIUM 2Challenging cases: dermoscopy quiz

SYMPOSIUM 3Biology of skin cancer


17:30 – 18:45 SYMPOSIUM 4Management of nevi

SYMPOSIUM 5Barriers to access to innovative medicines and successful access schemes in Europe: multistakeholder panel discussion

SYMPOSIUM 6Occupational skin cancers

7w w w . e a d o 2 0 2 0 . c o m


09:00 – 09:15 OPENING CEREMONYCHAIRS: Matilda Bylaitė-Bučinskienė (Vilnius, Lithuania)

Claus Garbe (Tuebingen, Germany)

09:15 – 12:30 DERMATOSCOPY COURSE 1CHAIRS: Iris Zalaudek (Trieste, Italy)

Aimilios Lallas (Thessaloniki, Greece)Harald Kittler (Vienna, Austria)

09:15 – 09:33 Pattern recognition and pattern analysis Harald Kittler (Vienna, Austria)

09:35 – 09:53 Colors: Black beauties and pink panthers Aimilios Lallas (Thessaloniki, Greece)

09:55 – 10:13 Case studies: What would a novice do Claudio Conforti (Trieste, Italy)

10:15 – 10:33 The beginners guide to avoid mistakes Giuseppe Argenziano (Naples, Italy)

10:35 – 10:53 Gray Color and its significance Iris Zalaudek (Trieste, Italy)

10:55 – 11:13 Nodules on the face – clues for benign and malignant lesions Susanna Puig (Barcelona, Spain)

11:15 – 11:33 Case studies: Monitoring – when to cut out and when to continue Josep Malvehy (Barcelona, Spain)

11:35 – 11:53 What is so special on special locationsLuc Thomas (Lyon, France)

11:55 – 12:13 Case studies: Real lifeLidija Kandolf-Sekulovic (Belgrade, Serbia)

12:15 – 12:28 Panel discussion


13:15 – 14:15 KEYNOTE LECTURES 1CHAIRS: Matilda Bylaitė-Bučinskienė (Vilnius, Lithuania)


13:15 – 13:45 Skin cancer preventionJean Jacques Grob (Marseille, France)

13:45 – 14:15 Classification of melanomaBoris Bastian (San Francisco, USA)


ALFA HALL

ALFA HALL

ALFA HALL

ALFA HALL

Monday, October 12

Mon

day,

Oct

ober

12

Dermatoscopy course




Symposium




15:30 – 17:00 SYMPOSIUM 1ADVANCED BCC CLASSIFICATION AND TREATMENTCHAIRS: Jean Jacques Grob (Marseille, France)

Nicole Basset-Seguin (Paris, France)

15:30 – 15:45 How to classify and stage BCC?Jean Jacques Grob (Marseille, France)

15:48 – 16:03 SMO inhibitorsNicole Basset-Seguin (Paris, France)

16:06 – 16:21 Best strategies using SMO inh (on/off intermittent, neoadjuvant.)Brigitte Dréno (Nantes, France)

16:24 – 16:39 What place for immunotherapy in BCC?Iris Zalaudek (Trieste, Italy)

16:42 – 16:57 Update: guidelinesKetty Peris (Rome, Italy)


17:30 – 18:45 SYMPOSIUM 4MANAGEMENT OF NEVICHAIRS: Giuseppe Argenziano (Naples, Italy)

Harald Kittler (Vienna, Austria)

17:30 – 17:42 The comparative approach and beyondGiuseppe Argenziano (Naples, Italy)

17:45 – 17:57 The “dysplastic” nevusHarald Kittler (Vienna, Austria)

18:00 – 18:12 The “Spitz” nevusAimilios Lallas (Thessaloniki, Greece)

18:15 – 18:27 Digital monitoring: best indicationsElvira Moscarella (Naples, Italy)

18:30 – 18:42 The blue and the non-blue congenital nevusSusanna Puig (Barcelona, Spain)

ALFA HALL

ALFA HALL

Mon

day,

Oct

ober

12

Mon

day,

Oct

ober

12

Monday, October 12

Dermatoscopy course




Symposium

9w w w . e a d o 2 0 2 0 . c o m


09:15 – 12:30 SKIN CARE IN ORGAN TRANSPLANT PATIENTS EUROPESATELLITE SYMPOSIUM AT THE EADO CHAIRS: Alexandra Geusau and Deniz Seckin

09:15 – 09:20 Welcome and introduction Alexandra Geusau

09:20 – 09:40 Keratinocyte skin cancer incidence after organ transplantationPetter Gjersvik

09:40 – 10:10 Considerations in the Dermatologic Care of Organ Transplant Recipients of ColorChristina Lee Chung

10:10 – 10:40 AK therapy and skin cancer prevention in high-risk transplant recipients (including Q&A)Klara Mosterd

10:40 – 11:00 Checkpoint inhibitor therapy for cancer in solid organ transplant recipients: A systematic review (including Q&A)Celeste Lebbé

11:00 – 11:05 SHORT BREAK

CHAIRS: Charlotte M. Proby and Elsemieke Plasmeijer

11:05 – 11:25 Rare skin cancers and immunosuppression (including Q&A)Catherine Harwood

11:25 – 11:55 Skin cancer in chronic lymphocytic leukemiaUlrike Leiter and Andreas Meiwes

CHAIRS / TUMOUR BOARD: Carla Ferrandiz-Pulido,

Veronique del Marmol, Mirjam Nägeli, Elsemieke Plasmeijer

11:55 – 12:20 Tumour Board and expert panel discussion: difficult to treat casesCase 1, Case 2, and Case 3 (each 10 min presentation and 5 min Q&A) Case 1: Carla Ferrándiz-PulidoCase 2: Mirjam NägeliCase 3: Stella de Jong

12:20 – 12:30 Closing remarks

Mon

day,

Oct

ober

12

Mon

day,

Oct

ober

12

Monday, October 12BETA HALL

Dermatoscopy course




Symposium





15:30 – 17:00 SYMPOSIUM 2CHALENGING CASESCHAIRS: Aimilios Lallas (Thessaloniki, Greece)

Giovanni Pellacani (Modena, Italy)

15:30 – 16:10 Challenging cases: dermoscopy quizGiovanni Pellacani (Modena, Italy)

16:15 – 16:50 Challenging cases: dermoscopy quizAimilios Lallas (Thessaloniki, Greece)


17:30 – 18:45 SYMPOSIUM 5BARRIERS TO ACCESS TO INNOVATIVE MEDICINES AND SUCCESSFUL ACCESS SCHEMES IN EUROPE: MULTI-STAKEHOLDER PANEL DISCUSSIONCHAIRS: Lidija Kandolf-Sekulovic (Belgrade, Serbia)

Ana-Maria Forsea (Bucharest, Romania)

17:30 – 17:45 “Innovative medicines: the challenge of combining swift patient access and health system sustainability.” Vision of the Task Force Access to Medicines of ECLWard Rommel (Brussels, Belgium)

17:49 – 18:04 TBDIgoris Baikovskis (Vilnius, Lithuania)

18:07 – 18:22 Patient Access to Innovation – Is the industry perspective different?Alexander Roediger (Kriens, Switzerland)

18:25 – 18:40 When survival depends on access to expensive therapies. Lessons from the Melanoma Patient Network EuropeBettina Ryll (Stockholm, Sweden)

BETA HALL

BETA HALL

Monday, October 12

Mon

day,

Oct

ober

12

Dermatoscopy course




Symposium

11w w w . e a d o 2 0 2 0 . c o m


15:30 – 17:00 SYMPOSIUM 3BIOLOGY OF SKIN CANCERCHAIRS: Amaya Virós (Manchester, UK)

Reinhard Dummer (Zurich, Switzerland)

15:30 – 15:42 Extramammary pagetThierry Nordmann (Zurich, Switzerland)

15:45 – 15:57 New perspectives for the pathogenesis of cutaneous melanomaAmaya Virós (Manchester, UK)

16:00 – 16:12 MCC where does it come fromSara Valpione (Manchester, UK)

16:15 – 16:27 Biology of Dermatofibrosarcoma protuberansCeleste Lebbé (Paris, France)

16:30 – 16:42 New aspects of cutaneous lymphomasReinhard Dummer (Zurich, Switzerland)

16:45 – 16:57 The molecular signature of fast-growing melanomasCaroline Gaudy-Marqueste (Marseille, France)


17:30 – 18:45 SYMPOSIUM 6OCCUPATIONAL SKIN CANCERSCHAIRS: Swen Malte John (Osnabrück, Germany)

Andrea Bauer (Dresden, Germany)

17:30 – 17:35 WelcomeAndrea Bauer (Dresden, Germany)Swen Malte John (Osnabrück, Germany)

17:35 – 17:48 UV exposure in outdoor workers across EuropeTimo Heepenstrick (Sankt Augustin, Germany)

17:51 – 18:04 Is basal cell carcinoma in outdoor workers an occupational disease?Andrea Bauer (Dresden, Germany)

18:07 – 18:20 Is malignant melanoma in outdoor workers an occupational disease?Swen Malte John (Osnabrück, Germany)

18:23 – 18:36 Efficacy of sunscreens in protecting against UVB radiationSanja Kezic (Amsterdam, The Netherlands)

18:39 – 18:52 Current standards in prevention and therapy of actinic keratosis and cutaneous squamous cell carcinomaClaas Ulrich (Berlin, Germany)

18:52 – 18:55 Questions

18:55 – 19:00 Wrap up

ZETA HALL

ZETA HALL

Monday, October 12

Mon

day,

Oct

ober

12




ALFA HALL BETA HALL ZETA HALL

08:30 – 10:00 SYMPOSIUM 7New diagnostic devises in skin cancers

SYMPOSIUM 8Predictive markers for immunotherapy in melanoma


10:30 – 12:00 SYMPOSIUM 9Medical treatment of melanoma

SYMPOSIUM 10Melanoma surgery



13:15 – 14:15 KEYNOTE LECTURES 2Cancer syndromesHow does immunotherapy work in cancer


SYMPOSIUM 11Update on management of actinic keratoses

WORKSHOP 1Spitzoid tumors



SYMPOSIUM 12Skin cancer prevention & screening

17:00 – 18:30 SYMPOSIUM 13Adjuvant treatment in melanoma

SYMPOSIUM 14The new European BCC guidelines


Tuesday, October 13

Tues

day,

Oct

ober

13

13w w w . e a d o 2 0 2 0 . c o m


08:30 – 10:00 SYMPOSIUM 7NEW DIAGNOSTIC DEVISES IN SKIN CANCERSCHAIRS: Josep Malvehy (Barcelona, Spain)

Giovanni Pellacani (Modena, Italy)

08:30 – 08:45 Confocal microscopy for melanoma diagnosis: evidence from Cochrane analysis to randomized trialGiovanni Pellacani (Modena, Italy)

08:48 – 09:03 Confocal microscopy for other skin cancers: in vivo and ex vivo applicationsJaviera Perez (Barcelona, Spain)

09:06 – 09:21 OCT for non-melanoma skin cancerJulia Welzel (Augsburg, Germany)

09:24 – 09:39 Linear-scanning OCTMariano Suppa, (Belgium, Brussels)

09:42 – 09:56 Other non-imaging tools and Artificial IntelligenceJosep Malvehy (Barcelona, Spain)


10:30 – 12:00 SYMPOSIUM 9MEDICAL TREATMENT OF MELANOMACHAIRS: Dirk Schadendorf (Essen, Germany)

Michael Postow (New York, USA)

10:30 – 10:50 What do we know about sequencing and combining?Dirk Schadendorf (Essen, Germany)

10:53 – 11:13 Are neoadjuvant trials for translational research or a registrational pathway for new treatments?Alexander van Akkooi (Amsterdam, The Netherlands)

11:16 – 11:36 Where are we 5-years later with combined CTLA-4 + PD1 checkpoint blockade?Celeste Lebbe (Paris, France)

11:39 – 11:59 Where are we 5-years later with BRAF directed targeted therapy?Helen Gogas (Athens, Greece)


13:15 – 14:15 KEYNOTE LECTURES 2CHAIRS: Hubert Pehamberger (Vienna, Austria)

Jean Jacques Grob (Marseille, France)

13:15 – 13:45 Cancer syndromesRoland Kaufmann (Frankfurt, Germany)

13:45 – 14:15 How does immunotherapy work in cancerThomas Gajewsky (Los Angeles, USA)

ALFA HALL

ALFA HALL

ALFA HALL

ALFA HALL

Tuesday, October 13

Tues

day,

Oct

ober

13

Dermatoscopy course




Symposium







17:00 – 18:30 SYMPOSIUM 13ADJUVANT TREATMENT IN MELANOMACHAIRS: Caroline Robert (Villejuif, France)

Jessica Hassel (Heidelberg, Germany)

17:00 – 17:15 Adjuvant immunotherapiesCaroline Robert (Villejuif, France)

17:18 – 17:33 Adjuvant targeted therapiesJessica Hassel (Heidelberg, Germany)

17:36 – 17:51 Adjuvant therapy in stage II melanomaAlexander Eggermont (Utrecht, The Netherlands)

17:54 – 18:09 Neoadjuvant approachesAlexander van Akkooi (Amsterdam, The Netherlands)

18:12 – 18:27 Panel discussion

08:30 – 10:00 SYMPOSIUM 8PREDICTIVE MARKERS FOR IMMUNOTHERAPY IN MELANOMACHAIRS: Brigitte Dréno (Nantes, France)

Christoph Hoeller (Vienna, Austria)

08:30 – 08:45 Predictive biomarkers for immunotherapy in advanced melanoma: Moving toward apersonalized medicine?Reinhard Dummer (Zurich, Switzerland)

08:48 – 09:03 Circulating biomarkers predictive of tumor response to immunotherapyChristoph Hoeller (Vienna, Austria)

09:06 – 09:21 Cell cycle regulator genes predicting responsiveness to melanoma immune therapy?Martin Röcken (Tübingen, Germany)

09:24 – 09:39 Predictive markers of induced immune-related adverse events to immunotherapyBrigitte Dréno (Nantes, France)

09:42 – 09:57 PET Imaging and early Immunotherapy Response: a new predictive toolDominik Bercazcy (Vienna, Austria)

ALFA HALL

ALFA HALL

ALFA HALL

BETA HALL

Tuesday, October 13

Tues

day,

Oct

ober

13

Dermatoscopy course




Symposium

15w w w . e a d o 2 0 2 0 . c o m


Tuesday, October 1310:00 – 10:30 BREAK, VIRTUAL EXHIBITION & E-POSTER VIEWING

10:30 – 12:00 SYMPOSIUM 10MELANOMA SURGERYCHAIRS: Roland Kaufmann (Frankfurt, Germany)

David Moreno (Seville, Spain)

10:30 – 10:42 Removal of nevi – Can we prevent Melanoma?Ricardo Vieira (Coimbra, Portugal)

10:45 – 10:57 Surgical standards in primary melanoma – Considerations of defect repairMichael Mühlstädt (Geneva, Switzerland)

11:00 – 11:12 Special aspects in surgery of Lentigo maligna melanomaCristina Magnoni (Modena, Italy)

11:15 – 11:27 Special aspects in surgery of acral MelanomasRoland Kaufmann (Frankfurt am Main, Germany)

11:30 – 11:42 SNB and CLND – current approaches and modificationsDavid Moreno-Ramirez (Seville, Spain)

11:45 – 12:57 Removal of distant Metastases – what are the indications and benefits?Alessandro Testori (Milan, Italy)

14:30 – 15:30 SYMPOSIUM 11UPDATE ON MANAGEMENT OF ACTINIC KERATOSESCHAIRS: Thomas Dirschka (Wuppertal, Germany)

Dimitrios Sgouros (Athens, Greece)

14:30 – 14:48 Actinic keratosis: Patients` perception and treatment barriersDimitrios Sgouros (Athens, Greece)

14:50 – 15:08 Evaluation of treatment outcome in actinic keratosis. What does it mean for efficacy?Rolf-Markus Szeimies (Recklinghausen, Germany)

15:10 – 15:28 News from the field – recent research on actinic keratosisThomas Dirschka (Wuppertal, Germany)

BETA HALL

BETA HALL

Tues

day,

Oct

ober

13

Dermatoscopy course




Symposium





16:00 – 17:00 SYMPOSIUM 12SKIN CANCER PREVENTION & SCREENINGCHAIRS: Veronique del Marmol (Brussels, Belgium)

Matilda Bylaitė-Bučinskienė (Vilnius, Lithuania)Dagmar Whitaker (Cape Town, South Africa)

16:00 – 16:12 Skin cancer awareness and early detection issues in the Baltic regionMatilda Bylaitė-Bučinskienė (Vilnius, Lithuania)

16:15 – 16:27 Sunscreen: the debateVeronique del Marmol (Brussels, Belgium)

16:30 – 16:42 Early detection for the biggest killersAna-Maria Forsea (Bucharest, Romania)

16:45 – 16:57 Skin cancer prevention and screening – what works and what doesn’t workDagmar Whitaker (Cape Town, South Africa)

17:00 – 18:30 SYMPOSIUM 14THE NEW EUROPEAN BCC GUIDELINES CHAIRS: Ketty Peris (Rome, Italy)

Maria Concetta Fargnoli (L’Aquila, Italy)

17:00 – 17:12 How to define common and difficult-to-treat BCCKetty Peris (Rome, Italy)

17:15 – 17:27 Which are the indications for surgical excision?Roland Kaufmann (Frankfurt, Germany)

17:30 – 17:42 When should we consider topical or destructive treatments?Maria Concetta Fargnoli (L’Aquila, Italy)

17:45 – 17:57 Which BCCs require medical therapy?Nicole Basset-Seguin (Paris, France)

18:00 – 18:12 Which follow-up schedule for which patients? Physicians recommendations and patient’s information.Veronique Bataille (London, UK)

18:15 – 18:27 How do we manage BCC lesions in NBCCS patients?Iris Zalaudek (Trieste, Italy)

BETA HALL

BETA HALL

Tuesday, October 13

Tues

day,

Oct

ober

13

Dermatoscopy course




Symposium

17w w w . e a d o 2 0 2 0 . c o m


Tuesday, October 1310:30 – 12:00 FREE COMMUNICATIONS 1

GENETICS, BIOLOGY, DIAGNOSIS AND STAGING OF MELANOMACHAIRS: Veronique Bataille (London, UK)

Antonio Costanzo (Milan, Italy)

10:30 – 10:40 FC01 Defining the prognostic role of microRNAs in cutaneous melanomaEmi Dika (Bologna, Italy)

10:43 – 10:53 FC02 MX2 is involved in regulation of cell cycle in melanoma cellsMarina Juraleviciute (Oslo, Norway)

10:56 – 11:06 FC03 AMBLor: a prognostic and companion biomarker for improved stratification of adjuvant therapy for AJCC stage II melanomaRob Ellis (Newcastle, UK)

11:09 – 11:19 FC04 Prognostic Risk Models Following AJCC Stage 1 Melanoma: A Systematic ReviewPatience Kunonga (Newcastle, UK)

11:22 – 11:32 FC05 Optimal Surveillance Strategies for AJCC Stage I Melanoma: The Health TechnologyAssessment (HTA) ApproachDiarmuid Coughlan (Newcastle, UK)

11:35 – 11:45 FC06 Validation of a clinicopathological and gene expression profile (CP-GEP) model to identify stage I and II melanoma patients at high risk for disease relapseE.E.A.P. Mulder (Amsterdam, The Netherlands)

11:48 – 11:58 FC07 Diagnostic accuracy of high-resolution ultrasound and fine needle aspiration forrecurrence and locoregional metastases at follow-up in patients treated initially for stage I or stage II melanoma: a systematic reviewMargaret Astin (Newcastle, UK)

14:30 – 15:30 WORKSHOP 1SPITZOID TUMORSCHAIRS:Laura Held (Friedrichshafen, Germany)

Aimilios Lallas (Thessaloniki, Greece)

14:30 – 14:50 Histopathology, immunohistochemistry and molecular alterations in Spitzoid lesionsLaura Held (Friedrichshafen, Germany)

14:55 – 15:15 Clinical and dermatoscopic morphology of spitzoid tumors and managementrecommendationsAimilios Lallas (Thessaloniki, Greece)

15:20 – 15:30 Discussion

ZETA HALL

ZETA HALL

Tues

day,

Oct

ober

13

Dermatoscopy course




Symposium




Tues

day,

Oct

ober

13

Tuesday, October 1315:30 – 16:00 BREAK, VIRTUAL EXHIBITION & E-POSTER VIEWING

17:00 – 18:30 FREE COMMUNICATIONS 2NON-MELANOMA SKIN CANCER CHAIRS: Alvydas Česas (Klaipėda, Lithuania)

Raimonds Karls (Riga, Latvia)

17:00 – 17:12 FC08 Surgery versus combined treatment with Curettage and Imiquimod for Nodularbasal cell carcinoma (SCIN): 1-year results of a non-inferiority, randomized controlled trialKelly Sinx (Maastricht, The Netherlands)

17:15 – 17:27 FC09 Daily practice data on 8 years’ experience with vismodegib in the NetherlandsKlara Mosterd (Maastricht, The Netherlands)

17:30 – 17:42 FC10 Improved sun protection after melanoma diagnosis improves survivalIchiro Okamoto (Vienna, Austria)

17:45 – 17:57 FC11 HeberFERON as a therapeutic option for the treatment of advanced, high risk andmultiple basal cell carcinomasIraldo Bello Rivero (Havana, Cuba)

18:00 – 18:12 FC12 Neoadjuvant Vismodegib and Mohs Micrographic Surgery for Locally AdvancedPeriocular Basal Cell CarcinomaGonzalez Abel (Buenos Aires, Argentina)

18:15 – 18:27 FC13 Intralesional oncolytic virotherapy results in tumor regression in cutaneous B-cell lymphomaEgle Ramelyte (Zurich, Switzerland)

ZETA HALL

Dermatoscopy course




Symposium

19w w w . e a d o 2 0 2 0 . c o m


Wednesday, October 14ALFA HALL BETA HALL ZETA HALL

08:30 – 10:00 SYMPOSIUM 15Advanced SCC

SYMPOSIUM 16Who should receive adjuvant therapy in melanoma


10:30 – 12:00 SYMPOSIUM 17Difficult to treat subtypes of melanoma

SYMPOSIUM 18The new European SCC guidelines



13:15 – 14:15 KEYNOTE LECTURES 3What is new in melanoma?What is new in keratinocyte skin cancer?


SYMPOSIUM 19Local therapies in melanoma

WORKSHOP 2Photodynamic therapy


16:00 – 16:58 SYMPOSIUM 20Metastatic Melanoma: Challenges

SYMPOSIUM 21Management of cutaneous toxicities

17:00 – 18:30 SYMPOSIUM 22Cutaneous lymphoma

SYMPOSIUM 23Rare skin tumors


18:30 – 19:00 CLOSING CEREMONY & AWARDS

Wed

nesd

ay, O

ctob

er 1

4

Dermatoscopy course




Symposium




08:30 – 10:00 SYMPOSIUM 15ADVANCED SCCCHAIRS: Axel Hauschild (Kiel, Germany)

Ulrike Leiter-Stöppke (Tuebingen, Germany)

08:30 – 08:45 Does surgery still play a role in advanced SCC?Roland Kaufmann (Frankfurt, Germany)

08:48 – 09:03 Impact of irradiation in the adjuvant and advanced settingRita Steponavičienė (Vilnius, Lithuania)

09:06 – 09:21 Chemotherapie and EGFR antibodies for advanced SCCEve Malbec (Bobigny, France)

09:24 – 09:39 PD-1 antibodies for advanced SCC patientsUlrike Leiter-Stöppke (Tuebingen, Germany)

09:42 – 09:57 Future aspects and new clinical trials for PD-1 antibodiesAxel Hauschild (Kiel, Germany)


10:30 – 12:00 SYMPOSIUM 17DIFFICULT TO TREAT SUBTYPES OF MELANOMACHAIRS: Lucie Heinzerling (Erlangen, Germany)

Céleste Lebbé (Paris, France)

10:30 – 10:50 Lentigo malignaEduardo Nagore (Valencia, Spain)

10:53 – 11:13 Mucosal melanomaMarkus Heppt (Erlangen, Germany)

11:16 – 11:36 Uveal MelanomaLucie Heinzerling (Erlangen, Germany)

11:39 – 11:59 Melanoma in organ transplant recipientsCeleste Lebbé (Paris, France)


13:15 – 14:15 KEYNOTE LECTURES 3CHAIRS: Ketty Peris (Rome, Italy)

Michael Postow (New York, USA)

13:15 – 13:45 What is new in melanoma?Michael Postow (New York, USA)

13:45 – 14:15 What is new in keratinocyte skin cancer?Axel Hauschild (Kiel, Germany)

ALFA HALL

ALFA HALL

ALFA HALL

ALFA HALL

Wed

nesd

ay, O

ctob

er 1

4

Wednesday, October 14

Dermatoscopy course




Symposium

21w w w . e a d o 2 0 2 0 . c o m




16:00 – 16:58 SYMPOSIUM 20METASTATIC MELANOMA: CHALLENGESCHAIRS: Maximilian Gassenmaier (Tuebingen, Germany)

Friedegund Meier (Dresden, Germany)

16:00 – 16:10 Patients with elevated LDHBastian Schilling (Würzburg, Germany)

16:12 – 16:22 Reversing a cold into a hot tumorOlivier Michielin (Lausanne, Switzerland)

16:24 – 16:34 Anti-PD-1 refractory melanomaPeter Mohr (Buxtehude, Germany)

16:36 – 16:46 Overcoming resistance mechanisms- Sequencing and combination strategiesReinhard Dummer (Essen, Germany)

16:48 – 16:58 Brain Metastasis: Multimodal therapyTeresa Amaral (Tübingen, Germany)

17:00 – 18:30 SYMPOSIUM 22CUTANEOUS LYMPHOMACHAIRS: Emannuella Guenova (Zurich, Switzerland)

Rudolf Stadler (Minden, Germany)

17:00 – 17:15 The blood signature of erythrodermiaPatrick M. Brunner (Vienna, Austria)

17:17 – 17:32 Diagnostic clues for cutaneous T lymphomasMaxime Batistella (Paris, France)

17:34 – 17:49 Prognostic factors for cutaneous T cell lymphomasJulia Scarisbrick (Birmingham, UK)

17:51 – 18:06 Treatment of early stage cutaneous T cell lymphoma: state of the artEmannuella Guenova (Zurich, Switzerland)

18:08 – 18:23 Treatment of late stage cutaneous T cell lymphoma: state of the artRudolf Stadler (Minden, Germany)

18:30 – 19:00 CLOSING CEREMONY & AWARDSCHAIRS: Matilda Bylaitė-Bučinskienė (Vilnius, Lithuania)


ALFA HALL

ALFA HALL

ALFA HALL

ALFA HALL


Wed

nesd

ay, O

ctob

er 1

4

Dermatoscopy course




Symposium




08:30 – 10:00 SYMPOSIUM 16WHO SHOULD RECEIVE ADJUVANT THERAPY IN MELANOMA?CHAIRS: Caroline Gaudy-Marqueste (Marseille, France)

Bastian Schilling (Wuerzburg, Germany)

08:30 – 08:50 Who should receive adjuvant therapy in melanoma in stage IV?Dirk Schadendorf (Essen, Germany)

08:53 – 09:13 Who should receive adjuvant therapy in melanoma in stage III?Bastian Schilling (Wurzburg, Germany)

09:16 – 09:36 Who should receive adjuvant therapy in melanoma in stage II?Caroline Gaudy-Marqueste (Marseille, France)

09:39 – 09:59 Who should receive adjuvant targeted therapy or adjuvant immunotherapy?Caroline Robert (Paris, France)


10:30 – 12:00 SYMPOSIUM 18THE NEW EUROPEAN SCC GUIDELINESCHAIRSDavid Moreno (Seville, Spain)

Ricardo Vieira (Coimbra, Portugal)

10:30 – 10:45 Risk assessment and stagingNicolle Kelleners-Smeets (Maastricht, The Netherlands)

10:48 – 11:03 Standard surgery and Mohs for primary BCCRicardo Vieira (Coimbra, Portugal)

11:06 – 11:21 Alternatives to surgery in selected casesRoland Kaufmann (Frankfurt, Germany)

11:24 – 11:39 Surgery for regional nodal diseaseDavid Moreno (Seville, Spain)

11:42 – 11:57 Systemic treatments for advanced SCCKetty Peris (Rome, Italy)

14:30 – 15:30 SYMPOSIUM 19LOCAL THERAPIES IN MELANOMACHAIRS: Robert H.I. Andtbacka (Boston, USA)

Christoph Hoeller (Vienna, Austria)

BETA HALL

BETA HALL

BETA HALL


Wed

nesd

ay, O

ctob

er 1

4

Dermatoscopy course




Symposium

23w w w . e a d o 2 0 2 0 . c o m


Wednesday, October 1415:30 – 16:00 BREAK, VIRTUAL EXHIBITION & E-POSTER VIEWING

16:00 – 17:00 SYMPOSIUM 21MANAGEMENT OF CUTANEOUS TOXICITIESCHAIRS: Pauline Tetu (Paris, France)

Caroline Robert (Villejuif, France)

16:00 – 16:17 Management of cutaneous toxicites related to immunotherapiesCaroline Robert (Villejuif, France)

16:20 – 16:37 Management of cutaneous toxicites related to BRAF MEK inhibitorsPauline Tetu (Paris, France)

16:40 – 18:00 Management of cutaneous toxicities of emergent therapies in oncologyVincent Sibaud (Toulouse, France)

17:00 – 18:30 SYMPOSIUM 23RARE SKIN TUMORSCHAIRS: Judith Oláh (Szeged, Hungary)

Peter Arenberger (Prague, Czech Republic))

17:00 – 17:20 Merkel cell carcinoma-update 2020 Erika Varga (Szeged, Hungary)

17:23 – 17:43 Electrochemotherapy in the management of rare skin tumoursJudith Oláh (Szeged, Hungary)

17:46 – 18:06 Rare skin tumors overviewPeter Arenberger (Prague, Czech Republic)

18:09 – 18:29 Dermatofibrosarcoma protuberansMarek Pasek (Prague, Czech Republic)

BETA HALL

BETA HALL

Wed

nesd

ay, O

ctob

er 1

4

Dermatoscopy course




Symposium




10:30 – 12:00 FREE COMMUNICATIONS 3MELANOMA TREATMENTCHAIRS: Susanna Puig (Barcelona, Spain)

Željko Mijušković (Belgrade, Serbia)

10:30 – 10:40 FC14 Real-world outcomes on health-related quality of life in the non-interventional study NICO in GermanyPeter Mohr (Buxtehude, Germany)

10:43 – 10:53 FC15 Prognosis and management of BRAF V600E-mutated pregnancy-associated melanomaDimitrios C. Ziogas (Athens, Greece)

10:56 – 11:06 FC16 First-line immunotherapy with nivolumab plus ipilimumab versus targeted therapy with BRAF plus MEK inhibitors in patients with BRAF-mutant advanced melanoma: A real-world analysisAnna C. Pavlick (Princeton, USA)

11:09 – 11:19 FC17 Real-world efficacy of anti-PD-1 antibodies in advanced subungual melanoma: The large multicenter retrospective Japanese Acral Melanoma PD-1 (JAMP) study of 70 casesYasuhiro Nakamura (Osaka, Japan)

11:22 – 11:32 FC18 2-year (yr) results and biomarker analysis of a phase 2, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL)Reinhard Dummer (Zurich, Switzerland)

11:35 – 11:45 FC19 A retrospective chart review study of realworld use of talimogene laherparepvec in unresectable stage IIIB-IVM1a melanoma in four European countriesA.C.J. van Akkooi (Amsterdam, The Netherlands)

11:48 – 11:58 FC20 Final results of phase II trial (MIRACULUM) of the novel PD-1 inhibitor prolgolimabin patients with advanced melanomaIgor Samoylenko (Moscow, Russia)

ZETA HALL


Wed

nesd

ay, O

ctob

er 1

4

Dermatoscopy course




Symposium

25w w w . e a d o 2 0 2 0 . c o m


14:30 – 15:30 WORKSHOP 2PHOTODYNAMIC THERAPYCHAIRS: Merete Haedersdal (Copenhagen, Denmark)

Rolf-Markus Szeimies (Recklinghausen, Germany)

14:30 – 14:42 PDT for AK, including DL-PDTRolf-Markus Szeimies (Recklinghausen, Germany)

14:45 – 14:57 PDT for BCCNicolle Kelleners-Smeets (Maastricht, The Netherlands)

15:00 – 15:12 Optimizing PDTMerete Haedersdal (Copenhagen, Denmark)

15:15 – 15:27 PDT for AK/NMSC in transplant patientsKatrine Togsverd-Bo (Copenhagen, Denmark)


17:00 – 18:30 FREE COMMUNICATIONS 4NON-MELANOMA SKIN CANCERCHAIRS: Eduardo Nagore (Valencia, Spain)

Bohdan Lytvynenko (Kyiv, Ukraine)

17:00 – 17:10 FC21 Bowen’s Disease in the Netherlands (1989-2017): Nationwide Incidence Rates and Risk of Cutaneous Squamous Cell CarcinomaSelin Tokez (Utrecht, The Netherlands)

17:13 – 17:23 FC22 The Real Burden of Cutaneous Squamous Cell Carcinoma in The Netherlands:Nationwide Incidence Rates of First and Multiple TumorsSelin Tokez (Utrecht, The Netherlands)

17:26 – 17:36 FC23 5 years recurrence rate of cutaneous squamous cell carcinoma of the head and neckKarolina Nemeth (Chesterfield, UK)

17:39 – 17:49 FC24 Squamous cell carcinoma of the lip. Ninety-nine invasive tumors treated with Mohsmicrographic surgery. Local and regional recurrence. Prognostic factorsGonzalez Abel (Buenos Aires, Argentina)

17:52 – 18:02 FC25 A Multidisciplinary Consensus on the Treatment of Patients with Advanced Cutaneous Squamous Cell CarcinomaScott M. Dinehart (Miami, USA)

18:05 – 18:15 FC26 Pembrolizumab for Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC): Efficacy per Immune-Related RECIST in KEYNOTE-629 Jean-Jacques Grob (Paris, France)

18:18 – 18:28 FC27 Efficacy and safety of immune checkpoint inhibitor cemiplimab in patients with locally advanced or metastatic squamocellular carcinomaGiulia Spallone (Rome, Italy)

ZETA HALL

ZETA HALL


Wed

nesd

ay, O

ctob

er 1

4

Dermatoscopy course




Symposium



CONGRESS FACULTY16th EADO CONGRESS

Prof. dr. Matilda Bylaitė-Bučinskienė (Vilnius, Lithuania), Congress PresidentProf. dr. Claus Garbe (Tuebingen, Germany), Congress President

APetr Arenberger, Prague, Czech RepublicGuiseppe Argenziano, Naples, Italy

BBoris Bastian, San Francisco, USAVeronique Bataille, London, United KingdomAndrea Bauer Dresden, GermanyJurgen Becker, Essen, GermanyChristian Blank, Amsterdam, The Netherlands

CAlvydas Česas, Klaipėda, Lithuania

DVeronique Del Marmol, Brussels, BelgiumBrigitte Dreno, Nantes, FranceThomas Dirschka Wuppertal, GermanyReinhard Dummer, Zurich, Switzerland

EAlexander Eggermont, Utrecht, The Netherlands

FMaria Concetta Fargnoli, Rome, ItalyAnna-Maria Forsea, Bucharest, Romania

GThomas Gajewski, Chicago, USAMaximilian Gassenmaier Tuebingen, GermanyHelen Gogas, Athens, Greece

Stephan Grabbe, Mainz, GermanyJean Jacques Grob, Marseille, FranceEmannuella Guenova Zurich, Switzerland

HMerete Haedersdal Copenhagen, DenmarkHolger Hänßle, Heidelberg, GermanyAxel Hauschild, Kiel, GermanyChristoph Höller, Vienna, AustriaLucie Heinzerling Erlangen, GermanyLaura Held Friedrichshafen, Germany

JSwen Malte John Osnabrück, Germany

KLidija Kandolf-Sekulovic, Belgrade, SerbiaRaimonds Karls, Riga, LatviaRoland Kaufmann, Frankfurt, GermanyNicole Kelleners-Smeets, Maastricht, The NetherlandsHarald Kittler, Vienna, Austria

LAimilios Lallas, Thessaloniki, GreeceCeleste Lebbe, Paris, FranceUlrike Leiter, Tuebingen, GermanyBohdan Lytvynenko, Kyiv, Ukraine

MJosep Malvehy, Barcelona, SpainFriedegund Meier, Dresden, GermanyOlivier Michielin, Lausanne, SwitzerlandZeljko Mijuskovic, Belgrade, SerbiaDavid Moreno-Ramirez, Seville, Spain

NEduardo Nagore, Valencia, Spain

OJudit Olah, Szeged, Hungary

PHubert Pehamberger, Vienna, AustriaGiovanni Pellacani, Modena, ItalyKetty Peris, Rome, ItalyMichael Postow, New York, USASusana Puig, Barcelona, Spain

RCaroline Robert, Paris, France

SDirk Schadendorf, Essen, GermanyBastian Schilling, Wuerzburg, Germany

TAlessandro Testori, Milan, ItalyLuc Thomas, Lyon, FranceRudolf Stadler, Minden, GermanyRolf-Markus Szeimies, Recklinghausen, Germany

VRicardo Vieira, Coimbra, PortugalAmaya Viros, Manchester, United Kingdom

WDagmar Whitaker, Cape Town, South Africa

ZIris Zalaudek, Trieste, Italy

27w w w . e a d o 2 0 2 0 . c o m

GENERAL INFORMATION16th EADO CONGRESS


Virtual congress dateOctober 12-14, 2020

Virtual congress timeIMPORTANT: Congress will be held on CET (Central European Time) Albania, Andorra, Austria, Belgium, Bosnia and Herzegovina, Croatia, Czech Republic, Denmark, France, Germany, Hungary, Italy, Kosovo, Liechtenstein, Luxembourg, North Macedonia, Malta, Monaco, Montenegro, Netherlands, Norway, Poland, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden and Switzerland

Virtual congress platformVirtual congress will be held on the congress webpage. Please visit www.eado2020.com for further information.Please visit https://eado2020.com/log-in-to-virtual/ for direct log in to the Virtual congress.

ExhibitionA virtual industrial exhibition will be provided. Please visit the exhibition at the website.

Language and translation

The official language of the meeting will be English. Simultaneous translation will not be provided.

RegistrationPlease visit: https://eado2020.com/registration/ for the information on registration.

Congress secretariatKONTEMPUSLokiu str. 8-9,Vilnius, LithuaniaLT- 08109. Email: [email protected]: + 370 618 77177

Claus Garbe, M.D. Professor of DermatologyPresident of the European Association of DermatoOncology (EADO)

Center for DermatooncologyDepartment of DermatologyEberhard Karls University, Tuebingen,Liebermeisterstr. 2572074 Tuebingen, Germany

Prof. dr. Matilda Bylaitė-BučinskienėProfessor in dermatovenereologyPresident of Lithuanian Association of Dermatovenereologists

Centre of DermatovenereologyClinic of Infectious diseases and DermatovenereologyFaculty of Medicine, Vilnius UniversityJ. Kairiūkščio str. 2 LT-08411

Congress organizers:

http://www.eado2020.com


SATELLITE SYMPOSIUM OVERVIEW16th EADO CONGRESS


Monday, October 12

Tuesday, October 13

14:30 – 15:30 SATELLITE SYMPOSIUM ISanofi Genzyme

14:30 – 15:30 Immune Checkpoint Blockade: A New Era in the Treatment of Nonmelanoma Skin Cancer

14:30 – 14:35 Welcome and Introduction Caroline Robert, MD, PhD (Chair)

14:35 – 14:50 Treatment for Locally Advanced/Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)Reinhard Dummer, MD

14:50 – 15:05 Exploring Research With Immunotherapy in CSCCAxel Hauschild, MD

15:05 – 15:20 Emerging Research With Immune Checkpoint Inhibitors in Advanced Basal Cell Carcinoma (BCC)Caroline Robert, MD, PhD (Chair)

15:20 – 15:30 Q&A and Concluding RemarksAll faculty

ALFA HALL

12:15 – 13:15 SATELLITE SYMPOSIUM II Bristol-Myers Squibb

12:15 – 13:15 Are Long-Term Data Changing Our Perspectives On Advanced Melanoma Treatment?

12:15 – 12:20 Welcome and Introduction Olivier Michielin (Lausanne, Switzerland)

12:20 – 12:35 Landmarks and More: A Review of Long-Term Outcomes Helen Gogas (Athens, Greece)

12:35 – 12:50 How are Long-Term Outcomes Impacting Our Practice and Opinions? Reinhard Dummer (Zurich, Switzerland)

12:50 – 13:10 Q&A and Interactive Workshop All faculty

13:10 – 13:15 Summary and Close Olivier Michielin (Lausanne, Switzerland)

ALFA HALL

29w w w . e a d o 2 0 2 0 . c o m


Tuesday, October 1314:30 – 15:30 SATELLITE SYMPOSIUM III

Kyowa Kirin International plc

14:30 – 15:30 Evolution in CTCL: a new therapeutic landscape

14:30 – 14:35 Welcome and introduction Prof. C. Klemke (Germany)

14:35 – 14:55 The patient journey from diagnosis to prognosis Prof. C. Klemke (Germany)

14:55 – 15:15 The evolving landscape for systemic treatments in CTCL: implications for practice Prof. Richard Cowan (Manchester, UK)

15:15 – 15:30 Panel discussion and summary Prof. C. Klemke (Germany), Prof. Richard Cowan (Manchester, UK)

ALFA HALL

16:00 – 17:00 SATELLITE SYMPOSIUM IVRegeneron

16:00 – 17:00 Advanced CSCC: What to Do When Surgery Just Isn’t Going to Cut It

16:00 – 16:10 Opening Remarks & Introductions Badri Modi, MD

16:10 – 16:30 Panel Discussion 1 — Immunotherapy in Advanced CSCC: Rationale Badri Modi, MD; Irene Braña, MD, PhD; Victor Moreno, MD, PhD

16:30 – 16:50 Panel Discussion 2 — Incorporating Immunotherapy into Practice: Safety, Patient Selection, and Emerging Therapies Badri Modi, MD; Irene Braña, MD, PhD; Victor Moreno, MD, PhD

16:50 – 17:00 Closing Remarks & Audience Questions Badri Modi, MD; Irene Braña, MD, PhD; Victor Moreno, MD, PhD

ALFA HALL


SATELLITE SYMPOSIUM OVERVIEW16th EADO CONGRESS


12:15 – 13:15 SATELLITE SYMPOSIUM VNovartis

12:15 – 13:15

12.15 – 12.20 Welcome and introduction Prof. Axel Hauschild (Germany)

12.20 – 12.35 An overview of the key adjuvant dataProf. Axel Hauschild (Germany)

12.35 – 12.50 Challenges in the adjuvant environmentDr. Igor Samoylenko (Russia)

12.50 – 13.05 Case study discussionsDr. Alvydas Cesas (Lithuania)

13.05 – 13.15 Summary and closeAll faculty

Wednesday, October 14 ALFA HALL

14.30 – 15.30 SATELLITE SYMPOSIUM VIPIERRE FABRE

TARGETING BRAF MUTATIONS IN ADVANCED MELANOMA Practical insights to optimize patient care

14.30 – 14.35 Welcome and introductionDirk Schadendorf (Essen, Germany)

14.35 – 14.45 Clinical trial experience: What can we expect from BRAF/MEK inhibition in advanced melanoma? Clinical caseMario Mandalà (Bergamo, Italy)

14.45 – 14.55 Views from the clinic: Real-world experience with encorafenib-binimetinibDirk Schadendorf (Essen, Germany)

14.55 – 15.05 Clinical trial experience: Treatment sequencing in advanced melanoma Clinical casePiotr Rutkowski (Warsaw, Poland)

15.05 – 15.15 Emerging sequencing approachesCaroline Robert (Paris, France)

15.15 – 15.25 Panel discussion: Evolving strategies and future perspectivesAll faculty

15.25 – 15.30 Closing remarksDirk Schadendorf (Essen, Germany)

ALFA HALL

ELCOME MEAE - mf.vu.lt€¦ · 18 FINAL PROGRAMME...

Documents

Transcript of ELCOME MEAE - mf.vu.lt€¦ · 18 FINAL PROGRAMME...